%0 Journal Article
%T Risk Factor Analysis for Secondary Malignancy in Dexrazoxane-Treated Pediatric Cancer Patients
%A Bin Cho
%A Hack Ki Kim
%A Hee Jo Baek
%A Hee Won Chueh
%A Hee Young Shin
%A Heung Sik Kim
%A Ho Joon Im
%A Hoi Soo Yoon
%A Hoon Kook
%A Hwang Min Kim
%A Hyery Kim
%A Hyo Seop Ahn
%A Hyoung Jin Kang
%A Hyoung Soo Choi
%A Jae Min Lee
%A Jae Wook Lee
%A Jeong Ok Hah
%A Ji Won Park
%A Ji Yoon Kim
%A Jong Jin Seo
%A Jun Ah Lee
%A Kyung Duk Park
%A Kyung-Nam Koh
%A Mee Jeong Lee
%A Meerim Park
%A Nack-Gyun Chung
%A Sang Kyu Park
%A Seokyung Hahn
%A Yoshifumi Kawano
%A Young Ho Lee
%J Archive of "Cancer Research and Treatment : Official Journal of Korean Cancer Association".
%D 2019
%R 10.4143/crt.2017.457
%X Dexrazoxane has been used as an effective cardioprotector against anthracycline cardiotoxicity. This study intended to analyze cardioprotective efficacy and secondary malignancy development, and elucidate risk factors for secondary malignancies in dexrazoxane-treated pediatric patients
%K Dexrazoxane
%K Childhood
%K Cancer
%K Anthracyclines
%K Risk factors
%K Second neoplasm
%U https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6333985/